Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Potentiated activation of VLA-4 and VLA-5 accelerates proplatelet-like formation.
Matsunaga T, Fukai F, Kameda T, Shide K, Shimoda H, Torii E, Kamiunten A, Sekine M, Yamamoto S, Hidaka T, Kubuki Y, Yokokura S, Uemura M, Matsuoka A, Waki F, Matsumoto K, Kanaji N, Ishii T, Imataki O, Dobashi H, Bandoh S, Shimoda K. Matsunaga T, et al. Among authors: kanaji n. Ann Hematol. 2012 Oct;91(10):1633-43. doi: 10.1007/s00277-012-1498-y. Epub 2012 May 29. Ann Hematol. 2012. PMID: 22644786
Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005).
Kanaji N, Ichihara E, Tanaka T, Ninomiya T, Kozuki T, Ishikawa N, Nishii K, Shoda H, Yamaguchi K, Kawakado K, Toyoda Y, Inoue M, Miyatake N, Watanabe N, Inoue T, Mizoguchi H, Komori Y, Kojima K, Kadowaki N. Kanaji N, et al. Lung. 2024 Feb;202(1):63-72. doi: 10.1007/s00408-023-00669-9. Epub 2024 Jan 24. Lung. 2024. PMID: 38265672 Free PMC article.
A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations.
Ninomiya T, Ishikawa N, Kozuki T, Kuyama S, Inoue K, Yokoyama T, Kanaji N, Yasugi M, Shibayama T, Aoe K, Ochi N, Fujitaka K, Kodani M, Ueda Y, Watanabe K, Bessho A, Sugimoto K, Oze I, Hotta K, Kiura K. Ninomiya T, et al. Among authors: kanaji n. Lung Cancer. 2023 Oct;184:107349. doi: 10.1016/j.lungcan.2023.107349. Epub 2023 Aug 19. Lung Cancer. 2023. PMID: 37651927 Clinical Trial.
Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.
Kuribayashi T, Ohashi K, Nishii K, Ninomiya K, Tsubata Y, Ishikawa N, Kodani M, Kanaji N, Yamasaki M, Fujitaka K, Kuyama S, Takigawa N, Fujimoto N, Kubota T, Inoue M, Fujiwara K, Harita S, Takata I, Takada K, Okawa S, Kiura K, Hotta K. Kuribayashi T, et al. Among authors: kanaji n. J Cancer Res Clin Oncol. 2024 Feb 12;150(2):89. doi: 10.1007/s00432-024-05618-4. J Cancer Res Clin Oncol. 2024. PMID: 38347279 Free PMC article.
Small cell lung cancer associated with systemic sclerosis.
Kanaji N, Fujita J, Bandoh S, Fukumoto T, Ishikawa M, Haba R, Ishii T, Kubo A, Ishida T. Kanaji N, et al. Intern Med. 2005 Apr;44(4):315-8. doi: 10.2169/internalmedicine.44.315. Intern Med. 2005. PMID: 15897643 Free article. Review.
89 results